In a study of melanoma with acquired resistance to ICI, JAK1-mutated melanoma cell lines were resistant to both Type I and II IFN signaling, while JAK2-mutated cells were resistant to Type II IFN but responded to Type I IFN signaling. The gene discussed is JAK2; the disease is melanoma.